Medical Stock News
September 2014 Stocks To Buy
September 9, 2014 Money Info Show to feature medical stocks to buy.
The Show was broadcast on Google hangouts.
Replay of the show
Part 1
Options Trading | How To Trade Options
Options trading, how to trade options and options trading strategies that work will be covered on the September 9 broadcast of the Money Info Stock Market News Today Radio Show.
Part 2 of the Show
Best Stocks To Buy
Cancer Treatment Medical Stock News
Money Info Show featured in the news:
Stock Market News Today Radio Show Features Medical Stock News, Options Trading and Best Stocks To Buy Now
and
Best Stocks To Buy CBLI Biotech Medical Stock To Be Featured On Where to invest Now Money info Show
http://www.pr-inside.com/best-stocks-to-buy-cbli-biotech-r4112691.htm
NOTE: Ms Levine was unable to attend the live broadcast.
It is rescheduled for next Tuesday, September 16th.
The show was to feature a live interview with
Rachel Levine, Vice President, Investor Relations
Cleveland BioLabs, Inc.
(NASDAQ Stock Symbol: CBLI)
Corporate Site: cbiolabs.com
Investors Conference Call Transcript — Click Here
Financials News – Click Here
LISTEN LIVE
Use this Link To Watch The Show:
www.princetonresearch.com/money-info-live.htm
Be On The Air With Us
Call In Your Questions
888-792-1590
Cleveland BioLabs (CBLI) Announces
Green Light to Submit
Pre-Emergency Use Authorization Application for Entolimod
Investment News Show
Money Info Show Airs
10 AM to 11 AM EDT
Every Tuesday
LISTEN LIVE
Money Info
The Princeton Research Money Info show features where to invest now, stock market, business, economy and financial investment news.
Money Info is hosted by Mike King and Charles Moskowitz.
Buffalo, NY – September 3, 2014 – Cleveland BioLabs, Inc. (NASDAQ:CBLI) today announced that the minutes from its meeting with the U.S. Food and Drug Administration (FDA) in July confirmed that the Company’s existing efficacy and safety data and animal-to-human dose conversion are sufficient to proceed with a pre-Emergency Use Authorization (pre-EUA) submission for entolimod for reducing the risk of death following exposure to potentially lethal irradiation occurring as the result of a radiation disaster.
See more at:
http://www.princetonresearch.com/medical-stock-news-cbli/
CBLI Stock News: Cleveland BioLabs stock soars –
Shares Up Big After Report Of
Positive FDA Opinion Issued For
Entolimod, Cancer Treatment And
Radiation Countermeasure Drug
• Shares of small cap medical stock, Cleveland BioLabs (CBLI +49.3%) leap on a considerable 23x surge in volume. The small cap medical stock reported that its existing safety and efficacy data and animal-to-human dose conversion are enough to proceed with a pre-Emergency Use Authorization submission to the FDA for the use of entolimod to reduce the risk of death following radiation exposure.
• The company’s opinion is based on the minutes from its July meeting with the agency. Regulatory approval will allow the use of entolimod in the occurrence of a radiological or nuclear emergency.
• In a study involving 179 non-human primates, a single IM shot of entolimod administered 25 hours following whole-body irradiation improved survival from 27.5% to 75%.
See more at:
More penny stocks to buy news:
Cleveland BioLabs Announces
Green Light to Submit
Pre-Emergency Use Authorization Application for Entolimod
BUFFALO, NY — (Marketwired) — 09/03/14 — Cleveland BioLabs, Inc. (CBLI) (NASDAQ: CBLI) today announced that the minutes from its meeting with theU.S. Food and Drug Administration (FDA) in July confirmed that the Company’s existing efficacy and safety data and animal-to-human dose conversion are sufficient to proceed with a pre-Emergency Use Authorization (pre-EUA) submission for entolimod for reducing the risk of death following exposure to potentially lethal irradiation occurring as the result of a radiation disaster.
Cleveland BioLabs Provides
Medical Countermeasures Against
Probable Terrorist Attacks
Terrorism is a real threat to America’s homeland as we have seen in recent news. However, we can take a little solace in the truth that the recent terrorist strike involved crude homemade non-radiological bombs. The fact remains that the world we are in is under constant threat from larger terrorist attacks, namely the sort that could involve “dirty bombs”.
A dirty bomb is a radiological weapon that includes radioactive material with typical explosives. Obviously, the aim of such a disgusting weapon is usually to inflict as much radioactive poisoning upon human beings as possible. In an effort to there will be the damage a radiological weapon might inflict around the American people, the United states Government began providing money to certain developmental firms.
One company that your U. S. Government possesses provided money to pertaining to developing radiological countermeasures is Cleveland BioLabs (NASDAQ: CBLI).
Cleveland BioLabs, is a developmental stage biopharmaceutical company aiming to treat cancer, prevent as well as treat acute radiation affliction (ARS), and counteract your toxic effects of airwaves and chemotherapies for oncology individuals. Let’s delve a little deeper into this interesting biotech company, along with others linked to preventative measures against prospective attacks.
The “Project BioShield Act” had been enacted on July 21 years old, 2004, as part of a broad strategy to support defend America against tools of mass destruction. Our elected representatives appropriated $5. 6 billion towards the Project BioShield Special Reserve Fund to guide the research, development, as well as acquisition of priority medical countermeasures against chemical, neurological, nuclear, and radiological (CBRN) threats. The Biomedical Advanced Study and Development Authority (BARDA)is the arm on the U. S. Department of Health insurance and Human Services charged along with allocating the funds. In a underreported development, Congress not too long ago earmarked additional funds pertaining to BARDA. The Pandemic as well as All-Hazards preparedness Reauthorization Act of 2013 was simply just signed into law on March 13th, designating one more $2. 8B for catastrophe related drug research as well as development.
In September of recently, BARDA awarded up in order to $106 million to Cytori Therapeutics (NASDAQ: CYTX) to develop cell therapies for winter burns and radiation harm. The aim of this deal was to evaluate and create new countermeasures pertaining to widespread thermal burns from mass casualty event like we saw in Fukushima inside 2011. For a company with a market cap of just $166 million and limited sources of revenue, a contract this large is important in furthering development associated with existing and possible future therapies which may potentially grow the business.